Page last updated: 2024-12-05

diphenylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diphenylamine is a white crystalline solid that is used as an antioxidant, a stabilizer, and a dye. It is also used as a reagent in the synthesis of other chemicals. Diphenylamine is synthesized by reacting aniline with nitrobenzene in the presence of a catalyst. Diphenylamine has a variety of effects on the body, including its use as an antioxidant in polymers, rubber, and fuels. It can also be used as a reagent in the synthesis of other chemicals. Diphenylamine is studied because it is a useful chemical that has a variety of applications. It is also an important industrial chemical. '

Diphenylamine: In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diphenylamine : An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11487
CHEMBL ID38688
CHEBI ID4640
SCHEMBL ID7527678
SCHEMBL ID229
SCHEMBL ID3685153
SCHEMBL ID6255037
SCHEMBL ID10932134
MeSH IDM0006515

Synonyms (121)

Synonym
HMS1788N11
BIDD:ER0338
AC-16417
MLS002152913
smr000777939
no scald
nsc-215210
phenylaniline
benzene, anilino-
aniline, n-phenyl-
anilinobenzene
n-phenylbenzenamine
benzene, (phenylamino)-
c.i. 10355
nsc215210
wln: rmr
big dipper
scaldip
DFA ,
styrenated diphenylamine
n-phenylbenzenamine, styrenated
einecs 270-485-3
benzenamine, n-phenyl-
diphenyl-amine
n-phenylaniline
inchi=1/c12h11n/c1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h1-10,13
NCGC00090889-01
nsc 215210
n-fenylanilin [czech]
no-scald
einecs 204-539-4
epa pesticide chemical code 038501
ai3-00781
caswell no. 398
ci 10355
deccoscald 282
ccris 4699
difenylamin [czech]
no-scald dpa 283
shield dpa
hsdb 1108
naugalube 428l
STK301666
122-39-4
n,n-diphenylamine
diphenylamine
diphenylamine, acs reagent, >=99%
(phenylamino)benzene
CHEBI:4640 ,
c6h5-nh-c6h5
D1229
NCGC00090889-02
benzenamine, n-phenyl-, styrenated
OPREA1_815288
NCGC00090889-03
diphenylamine, reagentplus(r), 99%
D0872
CHEMBL38688
diphenylamine, acs
n-phenylbenzeneamine
AKOS000119099
A804887
QSPL 033
NCGC00090889-04
NCGC00090889-05
n-fenylanilin
ec 204-539-4
unii-9n3cbb0biq
difenylamin
9n3cbb0biq ,
diphenyl amine
HMS3034E05
NCGC00259160-01
dtxcid001975
cas-122-39-4
tox21_201611
dtxsid4021975 ,
NCGC00254928-01
tox21_301026
SCHEMBL7527678
diphenylamine indicator
FT-0625252
n,n-diphenylamine [hsdb]
diphenylamine [mi]
EPITOPE ID:115002
SCHEMBL229
SCHEMBL3685153
n,n-diphenyl amine
ph2nh
phenyl aniline
n,n-di-phenylamine
n-(phenyl)aniline
SCHEMBL6255037
SCHEMBL10932134
mfcd00003014
J-520383
J-004797
F2190-0411
diphenylamine, pestanal(r), analytical standard
diphenylamine, puriss. p.a., redox indicator, acs reagent, reag. ph. eur., >=98% (gc)
diphenylamine, >=98%
diphenylamine, vetec(tm) reagent grade, 98%
diphenylamine, p.a.
diphenylamine 10 microg/ml in cyclohexane
diphenylamine 100 microg/ml in acetonitrile
n-phenylbenzenamine, 9ci
n-phenyl-aniline
n-phenyl-benzenamine
no scald dpa 283
2-biphenylyl-n-pyridyl-acetamide
anilino-benzene
(phenylamino)-benzene
25656-57-9
diphenylamine, acs grade
Q412265
EN300-18732
NC-0220
diphenylamine 1000 microg/ml in dichloromethane
Z90121252
usepa/opp pesticide code: 038501
n-phenylbenzamine

Research Excerpts

Overview

Diphenylamine (DPA) is a common contaminant at munitions-contaminated sites as well as at aniline manufacturing sites. It is a compound from the third European Union (EU) list of priority pollutants.

ExcerptReferenceRelevance
"Diphenylamine (DPA) is an aniline derivative, used widely as an industrial antioxidant, dye mordant, and agricultural fungicide. "( Iron overload induced by diphenylamine triggers reactive oxygen species and apoptosis in the spleen of pregnant rats and their fetuses.
Atallah, MN; El-Borm, HT; Kandil, EH; Latif, HMAE, 2023
)
2.66
"Diphenylamine (DPA) is a common contaminant at munitions-contaminated sites as well as at aniline manufacturing sites. "( Pathway and evolutionary implications of diphenylamine biodegradation by Burkholderia sp. strain JS667.
Shin, KA; Spain, JC, 2009
)
2.06
"Diphenylamine (DPA) is an antioxidant compound that occurs naturally in several vegetables. "( Micronucleus frequency in human lymphocytes after exposure to diphenylamine in vitro.
Cervella, P; Delpero, M; Santovito, A, 2012
)
2.06
"Diphenylamine (DPA) is a compound from the third European Union (EU) list of priority pollutants. "( Diphenylamine and derivatives in the environment: a review.
Drzyzga, O, 2003
)
3.2
"Diphenylamine is a common structure of nonsteroidal anti-inflammatory drugs (NSAIDs) to uncouple mitochondrial oxidative phosphorylation and to cause a decrease in hepatocellular ATP content and hepatocyte injury. "( Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs.
Horie, T; Masubuchi, Y; Yamada, S, 2000
)
2

Effects

Diphenylamine has been isolated as one of the active antihyperglycemic agents of onion. The reaction has been modified to make it suitable for the estimation of DNA in the presence of sialic acid.

ExcerptReferenceRelevance
"Diphenylamine has a similar diarylamine bond as RR2."( Enzymatic treatment of sulfonated aromatic amines generated from reductive degradation of reactive azo dyes.
Bewtra, JK; Biswas, MM; Biswas, N; Taylor, KE, 2007
)
1.06
"Diphenylamine has been isolated as one of the active antihyperglycemic agents of onion. "( Diphenylamine, an antihyperglycemic agent from onion and tea.
Abdel Wahab, SM; El-Olemy, MM; Farrag, NM; Karawya, MS,
)
3.02
"Diphenylamine derivatives have been reported with good fungicidal, insecticidal, acaricidal, rodenticidal and/or herbicidal activities. "( Design, synthesis and structure-activity relationship of novel diphenylamine derivatives.
Guan, A; Huang, G; Lan, J; Li, H; Li, Z; Liu, CL; Xie, Y, 2016
)
2.12
"The diphenylamine reaction has been modified to make it suitable for the estimation of DNA in the presence of sialic acid."( THE ESTIMATION OF DEOXYRIBONUCLEIC ACID IN THE PRESENCE OF SIALIC ACID: APPLICATION TO ANALYSIS OF HUMAN GASTRIC WASHINGS.
CROFT, DN; LUBRAN, M, 1965
)
0.72
"Diphenylamine has a similar diarylamine bond as RR2."( Enzymatic treatment of sulfonated aromatic amines generated from reductive degradation of reactive azo dyes.
Bewtra, JK; Biswas, MM; Biswas, N; Taylor, KE, 2007
)
1.06
"Diphenylamine (DPA) has been utilized as an antioxidant in studies of lipid peroxidation. "( Diphenylamine: an unusual antioxidant.
Hebbel, RP; Rao, G; Sugihara, T, 1993
)
3.17

Actions

ExcerptReferenceRelevance
"Diphenylamine was found to inhibit the production of bacterioruberin."( Retention of the 4-pro-R hydrogen atom of mevalonate at C-2,2' of bacterioruberin in Halobacterium halobium.
Milborrow, BV; Swift, IE, 1980
)
0.98

Treatment

ExcerptReferenceRelevance
"Diphenylamine (DPA) treatment did not prevent DSB, contrary to superficial scald."( 'Diffuse skin browning' in 1-MCP-treated apples: etiology and systems of control.
Dupille, E; Larrigaudière, C; Recasens, I; Soria, Y; Vilaplana, R, 2010
)
1.08

Toxicity

ExcerptReferenceRelevance
" Findings in animal models have shown that adverse effects of numerous drugs with idiosyncratic hepatotoxicity in humans can be reproduced in the presence of coincident inflammatory cytokine signaling."( Cytokine-associated drug toxicity in human hepatocytes is associated with signaling network dysregulation.
Alexopoulos, LG; Cosgrove, BD; Griffith, LG; Hang, TC; Hendriks, BS; Lauffenburger, DA; Sorger, PK, 2010
)
0.36
" Relative to placebo treatment, no significant adverse effects of robenacoxib were recorded in either study for clinical observations, haematological and clinical chemistry variables or macroscopic or microscopic lesions at necropsy."( Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2.
Arnaud, JP; Goldenthal, EI; Gruet, P; Jung, M; King, JN; Lees, P; Seewald, W, 2011
)
0.37
"16 mmol/L), suggesting that phenazine in drinking water may have an adverse effect on human health."( Formation and cytotoxicity of a new disinfection by-product (DBP) phenazine by chloramination of water containing diphenylamine.
Li, Z; Lou, L; Zhou, W; Zhu, L, 2012
)
0.59
" Most frequent drug-related adverse events were diarrhea, rash, aspartate aminotransferase elevation, vomiting, and nausea."( A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH, 2014
)
0.4
" Frequent dose modifications due to grade 3 adverse events may have contributed to limited treatment effect."( A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH, 2014
)
0.4
" Safety endpoints included reports of adverse events, results of clinical examinations, including body weight, and clinical chemistry and hematology variables."( Clinical safety of robenacoxib in feline osteoarthritis: results of a randomized, blinded, placebo-controlled clinical trial.
Bienhoff, SE; Budsberg, SC; King, JN; King, S; Lascelles, BD; Roberts, ES; Roycroft, LM, 2016
)
0.43
"In all 193 cats and the subgroup of 40 animals with concurrent CKD, there were no differences between groups in frequencies of reported adverse events, body weight change or results of serum or urine chemistry or hematology variables."( Clinical safety of robenacoxib in feline osteoarthritis: results of a randomized, blinded, placebo-controlled clinical trial.
Bienhoff, SE; Budsberg, SC; King, JN; King, S; Lascelles, BD; Roberts, ES; Roycroft, LM, 2016
)
0.43
" The primary efficacy variable was treatment success/failure, with failure defined as the need for rescue therapy to control pain or withdrawal of the dog from the study due to an adverse event."( Efficacy and Safety of Injectable Robenacoxib for the Treatment of Pain Associated With Soft Tissue Surgery in Dogs.
Friton, G; Karadzovska, D; King, JN; King, S; Thompson, C, 2017
)
0.46
" No significant differences between the robenacoxib and placebo groups in the frequency of reported adverse events were observed."( Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs.
Friton, G; Karadzovska, D; King, JN; King, S; Thompson, CM, 2017
)
0.46
" All dogs were in good health through study termination and there were no serious adverse events during the course of the study."( Safety evaluation of the interchangeable use of robenacoxib (Onsior™) tablets and solution for injection in dogs.
Heit, MC; Helbig, R; King, SB; Toutain, CE, 2017
)
0.46
"No serious adverse events were reported."( Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.
Brossard, P; Helbig, R; King, SB; Toutain, CE, 2018
)
0.48
"Robenacoxib was well tolerated at doses from 2 to 10 mg/kg/day and this 6-month study supports the safe use of Onsior™ (robenacoxib) tablets in dogs for the intended dosing regimen."( Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.
Brossard, P; Helbig, R; King, SB; Toutain, CE, 2018
)
0.48
" All cats were in good health through study termination and there were no serious adverse events during the study."( Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats.
Heit, MC; Helbig, R; King, SB; Seewald, W; Stallons, LJ; Thompson, CM; Toutain, CE, 2020
)
0.56
" Safety was evaluated from reported adverse events (AEs) and abnormalities detected on hematology and serum and urine chemistry analyses."( Clinical safety of robenacoxib in cats with chronic musculoskeletal disease.
Adrian, DE; Forster, S; Friton, G; King, JN; Lascelles, BDX; Seewald, W, 2021
)
0.62
"50), but no related adverse clinical effects were detected."( Clinical safety of robenacoxib in cats with chronic musculoskeletal disease.
Adrian, DE; Forster, S; Friton, G; King, JN; Lascelles, BDX; Seewald, W, 2021
)
0.62
"An accurate, simple and safe method was developed for simultaneous determination of nitroglycerine (NG) and nitrocellulose (NC) in double base solid propellants (DB propellants)."( A simple and safe approach for simultaneous spectrophotometric determination of nitroglycerin and nitrocellulose in double base solid propellants.
Mardi, K; Zarei, AR, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were assessed and tumor biopsies were done to evaluate pharmacodynamics."( Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
Bentivegna, S; Chapman, PB; DePrimo, SE; Krishnamurthi, SS; LoRusso, PM; Malburg, L; Nabell, LM; Ricart, AD; Rinehart, JJ; Tan, W; Wilner, KD, 2010
)
0.36
"The purpose of this population analysis was to characterize the pharmacokinetic properties of robenacoxib in blood and stifle joint synovial fluid of dogs."( Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.
Burgener, C; Giraudel, JM; Gruet, P; Jung, M; King, JN; Letellier, IM; Peyrou, M; Silber, HE, 2010
)
0.36
"A two-compartment pharmacokinetic model with linear elimination was developed to describe blood concentrations of robenacoxib."( Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.
Burgener, C; Giraudel, JM; Gruet, P; Jung, M; King, JN; Letellier, IM; Peyrou, M; Silber, HE, 2010
)
0.36
" Results from previous feline studies showed that, despite a short half-life in blood, the effect of robenacoxib persisted for 24 h in clinical studies."( Pharmacokinetic/pharmacodynamic modelling of robenacoxib in a feline tissue cage model of inflammation.
Elliott, J; King, JN; Lees, P; Pelligand, L; Toutain, PL, 2012
)
0.38
" The population pharmacokinetic analysis performed showed that the 1-2mg/kg dosage chosen provided consistent robenacoxib exposure in a wide range of canine patients."( Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis.
Fink, M; Giraudel, JM; Gruet, P; Jung, M; King, JN; Letellier, I; Mochel, JP; Peyrou, M, 2013
)
0.39
" Individual animal pharmacokinetic and pharmacodynamic parameters for COX-1 and COX-2 inhibition were generated by PK/PD modelling."( Differential pharmacokinetics and pharmacokinetic/pharmacodynamic modelling of robenacoxib and ketoprofen in a feline model of inflammation.
Elliott, J; Hormazabal, V; King, JN; Lees, P; Pelligand, L; Toutain, PL, 2014
)
0.4
" Plasma levels of refametinib, refametinib metabolite M17, and sorafenib were measured for pharmacokinetic assessments."( A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT, 2016
)
0.43
" Refametinib was readily absorbed following oral administration (plasma half-life of ∼16 hours at the MTD), and pharmacokinetic parameters displayed near-dose proportionality, with less than 2-fold accumulation after multiple dosing."( A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT, 2016
)
0.43
" However, the multi-dose and pharmacodynamic studies are necessary to establish more accurately its safety and efficacy in sheep."( Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration.
Fadel, C; Giorgi, M; Lisowski, A; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effects of RDEA119/BAY 869766 as a single agent and in combination with rapamycin were studied in 3 early passage primary pancreatic cancer xenografts, OCIP19, 21, and 23, grown orthotopically."( Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Chang, Q; Chapman, MS; Hedley, DW; Miner, JN, 2010
)
0.36
"RDEA119/BAY 869766 alone or in combination with rapamycin showed significant growth inhibition in all the 3 models, with a significant decrease in the percentage of cells in S-phase, accompanied by a large decrease in bromodeoxyuridine labelling and cell cycle arrest predominantly in G1."( Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Chang, Q; Chapman, MS; Hedley, DW; Miner, JN, 2010
)
0.36
"The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY 86-9766 in monotherapy and in combination with sorafenib in orthotopic and subcutaneous hepatocellular carcinoma (HCC) models with different underlying etiologies in two species."( Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013
)
0.39
" Synergistic effects in combination with sorafenib were shown in Huh-7, Hep3B xenografts, and MH3924A allografts."( Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013
)
0.39
"BAY 86-9766 shows potent single-agent antitumor activity and acts synergistically in combination with sorafenib in preclinical HCC models."( Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K, 2013
)
0.39

Bioavailability

ExcerptReferenceRelevance
" In the normal unintoxicated animal an intramuscular injection of 20 mg kg-1 sodium nitrite will form 20% methemoglobin; however, in acute cyanide intoxication the associated severe bradycardia appears to limit the rate of absorption and thus the rapid formation of methemoglobin."( Effectiveness of intramuscularly administered cyanide antidotes on methemoglobin formation and survival.
Vick, JA; Von Bredow, JD,
)
0.13
" In general, systemic exposure to PD0325901 was comparable between routes of administration due to high PO bioavailability (56-109%)."( Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.
Brown, AP; Carlson, TC; Graziano, MJ; Loi, CM, 2007
)
0.34
" Mean bioavailability was 69% and median time to maximum concentration (Cmax) was 1 hour for cats after SC administration of robenacoxib, whereas mean bioavailability was 49% and 10% and median time to Cmax was 1 hour and 30 minutes after oral administration to cats after food withholding and after cats were fed their entire ration, respectively."( Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.
Jung, M; King, JN; Lees, P; Maurer, MP; Schmid, VB; Seewald, W, 2013
)
0.39
"For treatment of acute conditions in cats, it is recommended to administer robenacoxib by IV or SC injection, orally after food withholding, or orally with a small amount of food to obtain optimal bioavailability and Cmax."( Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats.
Jung, M; King, JN; Lees, P; Maurer, MP; Schmid, VB; Seewald, W, 2013
)
0.39
" It was efficacious against B-RAF as well as K-Ras driven xenograft models and showed-despite being orally bioavailable and not a P-glycoprotein substrate-much lower brain/plasma exposure ratios than PD325901."( Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.
Brittain, D; Hammer, S; Hartung, IV; Hillig, RC; Hitchcock, M; Neuhaus, R; Petersen, K; Pühler, F; Scholz, A; Siemeister, G, 2013
)
0.39
" Compound 14 showed a 95% and 67% inhibition of tumor ERK1/2 and Akt phosphorylation, respectively, at 2 h postadministration by Western blot analysis, confirming the bioavailability and efficacy of this bifunctional inhibitor strategy toward combined MEK1/PI3K inhibition."( Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
Blanks, AE; Galbán, S; Hong, H; Lombardi, RL; Nino, CA; Ross, BD; Van Dort, ME; Wang, H, 2016
)
0.43
"502 L/kg/h and the bioavailability was high (78%)."( Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats.
Elliott, J; King, JN; Mochel, JP; Pelligand, L; Soubret, A, 2016
)
0.43
" The mean bioavailability following SC and PO administrations were 45."( Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration.
Fadel, C; Giorgi, M; Lisowski, A; Poapolathep, A; Sartini, I; Łebkowska-Wieruszewska, B, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Several dosage schedules were evaluated to determine an effective, well tolerated and convenient regime."( Clinical evaluation of a new anthelmintic - C. 9333 Go./CGP 4540 in human hookworm infection.
Dalal, NJ; Shah, PN; Vakil, BJ, 1977
)
0.26
" Thirty-six animals of both sexes were divided into 6 groups of equal number, 4 groups being used for the 28 days dosing study and the remainder for investigation of recovery."( [Twenty-eight day repeated dose toxicity testing of diphenylamine in F344 rats].
Furuta, K; Hayashi, Y; Imaida, K; Shimoji, N; Takamura, N; Uneyama, C; Yazawa, R; Yoshida, J, 1989
)
0.53
" apiostumum in rhesus monkeys the drug showed 100% efficacy at a dosage of 60 mg/kg administered thrice at 12-hour intervals."( Anthelmintic efficacy of amoscanate (C 9333-Go/CGP 4540) against various infections in rodents, dogs and monkeys.
Deb, BN; Sen, HG, 1981
)
0.26
" Six weeks after dosing the treated rabbits and untreated controls were killed and examined."( Histological changes elicited in Schistosoma japonicum infected rabbits following curative chemotherapy with 4-isothiocyano-4'-nitro-diphenylamine (C9333-Go/CGP 4540).
Lewert, RM; Robinson, A, 1981
)
0.47
" Preliminary experiments determined dosage of formula and culture interval."( Validation of an in vitro nutrition model using an enteral formula in aged neutrophils.
Farriol, M; Orta, X; Rodríguez, R; Venereo, Y,
)
0.13
"2% Tween 80 for PO dosing and 20% beta-cyclodextran sulfobutyl ether in water (w:v) for IV dosing."( Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration.
Brown, AP; Carlson, TC; Graziano, MJ; Loi, CM, 2007
)
0.34
" Using pharmacokinetic and pharmacodynamic data, we show that maintaining adequate MEK inhibition throughout the dosing interval is likely more important than achieving high peak levels because greater efficacy was achieved with more frequent but lower dosing."( RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Appleby, T; Dadson, C; Hamatake, R; Iverson, C; Lai, C; Larson, G; Maderna, A; Miner, JN; Quart, B; Vernier, JM; Vo, T; Weingarten, P; Yeh, LT, 2009
)
0.35
" However, 10 and 15 mg BID continuous dosing and 10 mg BID 5 days on/2 days off schedules were associated with delayed development of RVO; thus, further enrollment to this trial was stopped."( Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
Bentivegna, S; Chapman, PB; DePrimo, SE; Krishnamurthi, SS; LoRusso, PM; Malburg, L; Nabell, LM; Ricart, AD; Rinehart, JJ; Tan, W; Wilner, KD, 2010
)
0.36
"The objectives of this study were to establish dose-response and blood concentration-response relationships for robenacoxib, a novel nonsteroidal anti-inflammatory drug with selectivity for inhibition of the cyclooxygenase (COX)-2 isoenzyme, in a canine model of synovitis."( Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog.
Jung, M; King, JN; Lees, P; Schmid, VB; Seewald, W; Spreng, DE, 2010
)
0.36
" These results may explain the good efficacy observed with once-daily dosing in clinical trials and the high safety index of robenacoxib in dogs."( Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.
Burgener, C; Giraudel, JM; Gruet, P; Jung, M; King, JN; Letellier, IM; Peyrou, M; Silber, HE, 2010
)
0.36
"This pilot study evaluated PD-0325901 on an intermittent dosing schedule."( Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.
Boasberg, PD; Bodkin, D; Daniels, GA; Garrett, CR; Redfern, CH; Ricart, AD, 2011
)
0.37
" The recommended minimum dosage for robenacoxib tablets in cats is 1 mg/kg once daily (range 1-2."( Safety of oral robenacoxib in the cat.
Hotz, R; King, JN; Lees, P; Reagan, EL; Roth, DR; Seewald, W, 2012
)
0.38
" Continuous daily dosing resulted in moderate accumulation at most dose levels."( Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Adjei, AA; Clendeninn, NJ; Dubowy, RL; Dy, GK; Eckhardt, SG; Gore, L; Iverson, C; Jeffers, M; Leffingwell, DP; Lewis, KD; Ma, WW; Miner, JN; Rajagopalan, P; Ramanathan, RK; Sheedy, B; Shen, Z; Von Hoff, DD; Weekes, CD; Weiss, GJ; Yeh, LT, 2013
)
0.39
"The purpose of this analysis was to investigate whether the recommended daily dosage of 1-2mg/kg robenacoxib provides consistent exposure when administered to dogs with chronic osteoarthritis (OA), and the need for dose adjustment in special patient populations."( Population pharmacokinetic analysis of blood concentrations of robenacoxib in dogs with osteoarthritis.
Fink, M; Giraudel, JM; Gruet, P; Jung, M; King, JN; Letellier, I; Mochel, JP; Peyrou, M, 2013
)
0.39
" The six amines were dosed in four vehicles (water and three generic water-based MWF formulations) and analyzed using a scintillation counter or gas chromatography/mass spectrometry."( Skin absorption of six performance amines used in metalworking fluids.
Baynes, RE; Brooks, JD; Roux, LN; Yeatts, JL, 2015
)
0.42
" Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable."( KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers.
Doherty, GJ; Kerr, EM; Martins, CP, 2017
)
0.46
" Thirty-two healthy, young, experimentally naïve, purebred Beagle dogs were administered 0 (sham control, Group 1), 2, 6, and 10 mg/kg robenacoxib (corresponding to the upper end of the dosage range [1X, Group 2] and multiples thereof [3X and 5X, Group 3 and 4]), orally once daily for 6 months."( Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.
Brossard, P; Helbig, R; King, SB; Toutain, CE, 2018
)
0.48
"Robenacoxib was well tolerated at doses from 2 to 10 mg/kg/day and this 6-month study supports the safe use of Onsior™ (robenacoxib) tablets in dogs for the intended dosing regimen."( Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations.
Brossard, P; Helbig, R; King, SB; Toutain, CE, 2018
)
0.48
" The RP2D with continuous dacomitinib dosing was 15 mg of dacomitinib plus 6 mg of PD-0325901 (21 days on/7 days off), but major toxicity, including rash (85%), diarrhoea (88%) and nausea (63%), precluded long-term treatment."( Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
Beijnen, JH; Bernards, R; de Vos, FYFL; Devriese, LA; Eskens, FALM; Huijberts, SCFA; Huitema, ADR; Lolkema, MPJK; Marchetti, S; Monkhorst, K; Opdam, FL; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM, 2020
)
0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
carotogenesis inhibitorAny inhibitor of the biosynthesis of carotenoids.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitorAn EC 1.3.99.* (oxidoreductase acting on donor CH-CH group with other acceptors) inhibitor that interferes with the action of phytoene desaturase (zeta-carotene-forming), EC 1.3.99.29, an enzyme of carotenoid biosynthesis that converts phytoene into zeta-carotene (zeta-carotene) via the symmetrical introduction of two double bonds at the C-11 and C-11' positions of phytoene.
antifungal agrochemicalAny substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties.
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
bridged diphenyl fungicideAny organic aromatic compound containing two phenyl (or substituted phenyl) groups attached to a single carbon or heteroatom and which has been used as a fungicide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
diphenylamine degradation37
echinenone and zeaxanthin biosynthesis (Synechocystis)112
staphyloxanthin biosynthesis421

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00240.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
LuciferasePhotinus pyralis (common eastern firefly)Potency71.45080.007215.758889.3584AID1224835
ClpPBacillus subtilisPotency31.62281.995322.673039.8107AID651965
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency38.88103.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency13.67150.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency43.62520.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency43.62520.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency68.58960.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency31.07210.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743042
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency24.31180.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.23310.001022.650876.6163AID1224893
progesterone receptorHomo sapiens (human)Potency48.50840.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.06840.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.48270.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.00570.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849
farnesoid X nuclear receptorHomo sapiens (human)Potency10.96220.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency61.06840.005428.02631,258.9301AID1346982
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency56.23410.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency68.58960.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency61.644819.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency44.26960.057821.109761.2679AID1159526; AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency68.58960.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency64.75280.000627.21521,122.0200AID743219
Glycoprotein hormones alpha chainHomo sapiens (human)Potency5.01194.46688.344810.0000AID624291
Cellular tumor antigen p53Homo sapiens (human)Potency76.91970.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km240.00007.00007.00007.0000AID214939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID613166Inhibition of PDK1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID288191Membrane retention in permeability experiment with artificial membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID613154Inhibition of FES expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 400 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID288185Permeability coefficient through artificial membrane in presence of stirred water layer2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID293642Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis time at 3 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID399323Hypoglycemic activity in glucose-fed rabbit assessed as reduction of plasma glucose at 10 mg/kg, po after 1.5 hrs
AID293644Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis time at 9 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID613169Inhibition of PIM1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613157Inhibition of FAK expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613163Inhibition of p38alpha expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID613147Inhibition of AKT1 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613170Inhibition of RIP2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID399325Hypoglycemic activity in glucose-fed rabbit assessed as reduction of plasma glucose at 10 mg/kg, po after 2.5 hrs
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID613145Inhibition of JNK1 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID399321Hypoglycemic activity in glucose-fed rabbit assessed as reduction of plasma glucose at 10 mg/kg, po after 0.5 hr
AID86389Inhibitory effect on L-triiodothyronine (L-T3) uptake by human HepG2 hepatoma cells at an application dose 10E-5 M1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class.
AID613173Inhibition of SYK expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID288188Permeability from apical to basolateral side of the Caco-2 cell membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID613162Inhibition of MK2 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID673777Cytotoxicity in UV-irradiated human U937 cells exposed to photosensitizer for 2 hrs before irradiation for 20 mins by WST-1 assay2012ACS medicinal chemistry letters, Apr-12, Volume: 3, Issue:4
Type 1 Phototherapeutic Agents. 2. Cancer Cell Viability and ESR Studies of Tricyclic Diarylamines.
AID399322Hypoglycemic activity in glucose-fed rabbit assessed as reduction of plasma glucose at 10 mg/kg, po after 1 hr
AID293668Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis inhibition time at 9 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID613160Inhibition of ITK expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID21661Calculated partition coefficient (clogP) (PALLAS)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class.
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID613168Inhibition of PI3Kdelta expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613149Inhibition of ASK1 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613153Inhibition of EGFR expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613167Inhibition of PI3Kalpha expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613155Inhibition of ErbB2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613172Inhibition of SGK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613150Inhibition of AurA expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID293643Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis time at 6 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID293669Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis inhibition time at 12 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID293646Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis time at 15 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID399319Hypoglycemic activity in fasting rabbit assessed as reduction of plasma glucose at 10 mg/kg, po
AID293670Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis inhibition time at 15 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID293667Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis inhibition time at 6 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID613143Inhibition of IKK-beta expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613151Inhibition of AurB expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613152Inhibition of B-Raf expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 400 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613165Inhibition of PAK2 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613144Inhibition of PI3Kgamma expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613148Inhibition of AKT2 expressed in Escherichia coli or baculovirus-infected insect cells using gamma-[33P]ATP at 400 uM by scintillation proximity assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID288189Permeability from basolateral to apical side of the Caco-2 cell membrane2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID613156Inhibition of ErbB4 expressed in Escherichia coli or baculovirus-infected insect cells at 400 to 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID399326Hypoglycemic activity in rabbit assessed as reduction of plasma glucose at 10 mg/kg, po after 2 hrs
AID613158Inhibition of GSK3-beta expressed in Escherichia coli or baculovirus-infected insect cells using ATP as substrate at 667 uM by fluorescence polarization assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID293645Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis time at 12 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID613171Inhibition of ROCK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID19429Partition coefficient (logP)1997Journal of medicinal chemistry, May-09, Volume: 40, Issue:10
Inhibition of thyroid hormone uptake by calcium antagonists of the dihydropyridine class.
AID613164Inhibition of PAK1 expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by IMAP assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID293666Inhibition of AAPH-induced hemolysis in human erythrocytes assessed as hemolysis inhibition time at 3 uM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Free-radical-scavenging effect of carbazole derivatives on AAPH-induced hemolysis of human erythrocytes.
AID613161Inhibition of JAK3 expressed in Escherichia coli or baculovirus-infected insect cells at 667 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID613159Inhibition of IGF1R expressed in Escherichia coli or baculovirus-infected insect cells at 400 uM by TR-FRET assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Selectivity of kinase inhibitor fragments.
AID399324Hypoglycemic activity in glucose-fed rabbit assessed as reduction of plasma glucose at 10 mg/kg, po after 2 hrs
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (963)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990310 (32.19)18.7374
1990's55 (5.71)18.2507
2000's120 (12.46)29.6817
2010's418 (43.41)24.3611
2020's60 (6.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.91 (24.57)
Research Supply Index6.96 (2.92)
Research Growth Index4.95 (4.65)
Search Engine Demand Index118.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.91)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials44 (4.37%)5.53%
Reviews18 (1.79%)6.00%
Case Studies6 (0.60%)4.05%
Observational1 (0.10%)0.25%
Other937 (93.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]